[Prevalence and initial management of overactive bladder in France: A cross-sectional study].
OBJECTIVE
To determine the prevalence of overactive bladder (OAB) syndrome in France and gather data about initial patient trajectories in the healthcare system.


METHODS
A dedicated questionnaire (41 questions) has been sent to a 12,000 sample of people representative of the global population. The following data were investigated: social and demographic features, medical history, Urinary Symptom Profile questionnaire, bother, history of symptoms, care seeking and treatments received. Patient were considered having OAB in case if presenting at least two episodes of urgency per week, or being under treatment of OAB. OAB prevalence was the main outcome, and associated factors were characterized by univariate and multivariate analysis.


RESULTS
Based on 8842 available questionnaires, the global prevalence of OAB was estimated to be 14.4%. Prevalence was significantly higher in women, older age groups, as well as obesity, irritable bowel syndrome, urinary tract infections, enuresia, constipation, anxiety/depression, neurological diseases, sleep apnea syndrome, asthma, chronic obstructive pulmonary disease, diabetes and hypertension. Only 34.6% of patients with OAB had visited a health practitioner for this problem. General practitioners were most frequently implicated in patient primary care and evaluation. Seventy-two percent of patients with OAB had had additional investigations (mostly a urine culture) and only 6% of patients had to complete a bladder diary. The most frequent treatment option was oral antimuscarinics. Physical therapy and rehabilitation have been prescribed in 26% of cases, as well as dietary advice.


CONCLUSIONS
OAB is a frequent syndrome. Its prevalence increases with age, and OAB frequently concern elderly frail people with many other associated diseases.


METHODS
3.
Chirurgie urologique, université de Rouen, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France. Electronic address: jeannicolas.cornu@gmail.com.
J-N
JN
Cornu
Sorbonne universités, UPMC université Paris 06, GRC 01, GREEN, Group of Clinical Research in Neuro-Urology, 75005 Paris, France; Service de neuro-urologie et d'explorations périnéales, hôpital Tenon, AP-HP, 75020 Paris, France.
G
G
Amarenco
Chirurgie urologique, CHRU Le Bretonneau, 2, boulevard Tonnelé, 37000 Tours, France.
F
F
Bruyere
Faculté de médecine Pierre-et-Marie-Curie, Paris 6, hôpital universitaire Pitié-Salpetrière, AP-HP, 83, boulevard de l'Hôpital, 75013 Paris, France.
E
E
Chartier-Kastler
Gynécologie/obstétrique, CHU Caremeau, 4, rue Professeur-Robert-Debré, 30029 Nîmes, France.
B
B
Fatton
Chirurgie urologique, université de Rouen, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
P
P
Grise
Centre urologie Paris Opéra, 75009 Paris, France.
F
F
Haab
Astellas Pharma, 26, quai Michelet, CS 90067, 92309 Levallois-Perret cedex, France.
R
R
Bourouina
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D057566:Self Report; D053201:Urinary Bladder, Overactive / Q000453:epidemiology* / Q000628:therapy*; D055815:Young Adult
Anticholinergiques; Antimuscarinics; Hyperactivité vésicale; Management; Overactive bladder; Traitement